{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T07:09:41Z","timestamp":1772176181082,"version":"3.50.1"},"reference-count":31,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Muscles"],"abstract":"<jats:p>Eculizumab is a monoclonal antibody blocking the terminal complement protein C5. As demonstrated in the phase III randomized, placebo-controlled, REGAIN clinical trial, eculizumab is efficacious in acetylcholine receptor antibody (AChR-Ab)-positive refractory generalized myasthenia gravis (gMG) (Myasthenia Gravis Foundation of America\u2014MGFA class II\u2013IV). It has not been studied in severe myasthenic exacerbation or myasthenic crisis (MGFA V). A 73-year-old man diagnosed with myasthenia gravis AChR-Ab positivity came to our observation for symptoms of bulbar and ocular weakness and unresponsiveness or intolerability to conventional immunosuppressive therapies (prednisone and azathioprine). Due to the recurrent clinical worsening with intubation over a short-term period, the patient was treated with eculizumab. After 15 days of eculizumab treatment, we observed a significant recovery of clinical condition. We discharged the patient to an outpatient regimen, where he is continuing with maintenance doses of eculizumab and slowly tapering steroid intake. The use of eculizumab in myasthenic crises is still anecdotal. Our case aims to provide eculizumab benefit for refractory severe gMG in a practical, real-world setting beyond the criteria of the REGAIN study. Further studies are needed to evaluate the efficacy and safety of eculizumab in myasthenic crises.<\/jats:p>","DOI":"10.3390\/muscles3010005","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T06:12:58Z","timestamp":1707286378000},"page":"40-47","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Eculizumab as Additional Rescue Therapy in Myasthenic Crisis"],"prefix":"10.3390","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1396-7774","authenticated-orcid":false,"given":"Francesco","family":"Crescenzo","sequence":"first","affiliation":[{"name":"Neurology Unit, \u201cMater Salutis\u201d Hospital, AULSS 9 Scaligera, 37045 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattia","family":"Zanoni","sequence":"additional","affiliation":[{"name":"Neurology Unit, \u201cMater Salutis\u201d Hospital, AULSS 9 Scaligera, 37045 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Ferigo","sequence":"additional","affiliation":[{"name":"Neurology Unit, \u201cMater Salutis\u201d Hospital, AULSS 9 Scaligera, 37045 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Rossi","sequence":"additional","affiliation":[{"name":"Neurology Unit, \u201cMater Salutis\u201d Hospital, AULSS 9 Scaligera, 37045 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Grec\u00f2","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, \u201cMater Salutis\u201d Hospital, AULSS 9 Scaligera, 37045 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelica","family":"Lupato","sequence":"additional","affiliation":[{"name":"Neurology Unit, \u201cMater Salutis\u201d Hospital, AULSS 9 Scaligera, 37045 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Danese","sequence":"additional","affiliation":[{"name":"Neurology Unit, \u201cMater Salutis\u201d Hospital, AULSS 9 Scaligera, 37045 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Ajena","sequence":"additional","affiliation":[{"name":"Neurology Unit, \u201cMater Salutis\u201d Hospital, AULSS 9 Scaligera, 37045 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelangelo","family":"Turazzini","sequence":"additional","affiliation":[{"name":"Neurology Unit, \u201cMater Salutis\u201d Hospital, AULSS 9 Scaligera, 37045 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: The role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/BOR.0000000000000647","article-title":"Diagnosis and treatment of myasthenia gravis","volume":"31","author":"Mantegazza","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.athoracsur.2010.01.038","article-title":"Assessment of Robotic Thymectomy Using the Myasthenia Gravis Foundation of America Guidelines","volume":"89","author":"Goldstein","year":"2010","journal-title":"Ann. Thorac. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s13311-022-01181-3","article-title":"Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management","volume":"19","author":"Vanoli","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref_6","first-page":"255","article-title":"Clinical characteristics of refractory myasthenia gravis patients","volume":"86","author":"Suh","year":"2013","journal-title":"Yale J. Biol. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/14712598.2020.1786530","article-title":"Eculizumab for the treatment of myasthenia gravis","volume":"20","author":"Mantegazza","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"696385","DOI":"10.3389\/fneur.2021.696385","article-title":"Eculizumab Pharmacokinetics and Pharmacodynamics in Patients with Generalized Myasthenia Gravis","volume":"12","author":"Monteleone","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.4049\/jimmunol.179.12.8562","article-title":"Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis","volume":"179","author":"Zhou","year":"2007","journal-title":"J. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1634\/theoncologist.2008-0086","article-title":"FDA report: Eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"13","author":"Dmytrijuk","year":"2008","journal-title":"Oncologist"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1275533","DOI":"10.3389\/fneur.2023.1275533","article-title":"Rituximab treatment in myasthenia gravis","volume":"14","year":"2023","journal-title":"Front. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: The RINOMAX randomized clinical trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.nmd.2022.06.006","article-title":"Rituximab in myasthenia gravis: Efficacy, associated infections and risk of induced hypogammaglobulinemia","volume":"32","author":"Moga","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1111\/ene.15872","article-title":"Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis","volume":"30","author":"Pane","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","article-title":"Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4","volume":"12","author":"Verschuuren","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/acn3.51121","article-title":"Consistent improvement with eculizumab across muscle groups in myasthenia gravis","volume":"7","author":"Mantegazza","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"105630","DOI":"10.1016\/j.clineuro.2019.105630","article-title":"Temporal correlation between serum CH50 level and symptom severity of myasthenia gravis during eculizumab therapy","volume":"189","author":"Yanagidaira","year":"2020","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mus.27326","article-title":"The use of eculizumab in ventilator-dependent myasthenia gravis patients","volume":"64","author":"Usman","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1007\/s10072-023-06900-y","article-title":"Starting eculizumab as rescue therapy in refractory myasthenic crisis","volume":"44","author":"Vinciguerra","year":"2023","journal-title":"Neurol. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1007\/s00415-022-11222-8","article-title":"Eculizumab as a fast-acting rescue therapy in a refractory myasthenic crisis: A case report","volume":"269","author":"Strano","year":"2022","journal-title":"J. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1002\/mus.26124","article-title":"Eculizumab in refractory myasthenic crisis","volume":"58","author":"Yeo","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1756286420904207","DOI":"10.1177\/1756286420904207","article-title":"Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis","volume":"13","author":"Oyama","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1007\/s00415-021-10428-6","article-title":"Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19","volume":"268","author":"Oy","year":"2021","journal-title":"J. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101925","DOI":"10.1016\/j.ajoc.2023.101925","article-title":"Refractory generalized myasthenia gravis with myasthenic incomplete ophthalmoplegia successfully treated with eculizumab","volume":"32","author":"Weidmayer","year":"2023","journal-title":"Am. J. Ophthalmol. Case Rep."}],"container-title":["Muscles"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2813-0413\/3\/1\/5\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:56:22Z","timestamp":1760104582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2813-0413\/3\/1\/5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["muscles3010005"],"URL":"https:\/\/doi.org\/10.3390\/muscles3010005","relation":{},"ISSN":["2813-0413"],"issn-type":[{"value":"2813-0413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,7]]}}}